Last reviewed · How we verify
Leukocyte rich platelet rich plasma
Leukocyte-rich platelet-rich plasma (LR-PRP) concentrates platelets and white blood cells from autologous blood to deliver growth factors and immune cells that promote tissue healing and regeneration.
Leukocyte-rich platelet-rich plasma (LR-PRP) concentrates platelets and white blood cells from autologous blood to deliver growth factors and immune cells that promote tissue healing and regeneration. Used for Musculoskeletal injuries and degenerative conditions (e.g., osteoarthritis, tendinopathy, ligament injuries), Soft tissue repair and wound healing.
At a glance
| Generic name | Leukocyte rich platelet rich plasma |
|---|---|
| Sponsor | University Hospitals Cleveland Medical Center |
| Drug class | Autologous cell therapy / Regenerative medicine product |
| Modality | Biologic |
| Therapeutic area | Orthopedics / Regenerative Medicine |
| Phase | FDA-approved |
Mechanism of action
LR-PRP is prepared by centrifuging a patient's own blood to isolate a concentrate containing elevated levels of platelets, leukocytes, and fibrin. The platelets release growth factors (PDGF, VEGF, FGF, TGF-β) and the leukocytes provide additional cytokines and antimicrobial properties. This biological concentrate is injected directly into damaged tissues to stimulate angiogenesis, collagen deposition, and tissue repair.
Approved indications
- Musculoskeletal injuries and degenerative conditions (e.g., osteoarthritis, tendinopathy, ligament injuries)
- Soft tissue repair and wound healing
Common side effects
- Injection site pain or discomfort
- Temporary swelling or inflammation at injection site
- Infection risk (minimal with sterile technique)
Key clinical trials
- Platelet Rich Plasma for Musculoskeletal Conditions (NA)
- Low-Cost Platelet-Rich Plasma for Hemarthropathy (NA)
- Autologous BMA vs Saline and LAM + LP-PRP vs Saline Evaluations in Knee OA (PHASE2, PHASE3)
- Evaluation of Three Types of Injection for the Treatment of Lateral Epicondylalgia (NA)
- i-PRF & Root Surface Biomodification (NA)
- Leukocyte-rich PRP or Leukocyte-free PRP vs Placebo in the Treatment of Epicondylitis (NA)
- Use of Leukocyte-Rich PRP or Leukocyte-Free PRP in the Treatment of Hip Osteoarthritis (NA)
- Comparing Platelet Rich Plasma and Corticosteroid for Military & Civilian Patients With Glenohumeral Osteoarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: